FISH for Cutaneous Melanoma

**Background**

Melanoma is the deadliest form of skin cancer. In 2013, it is estimated that 76,690 new cases of melanoma will be diagnosed with 9,480 deaths.\(^1\)

Although the majority of melanomas can be distinguished from benign nevi on the basis of histologic criteria, a significant subset of melanocytic proliferations present conflicting features that preclude a definitive diagnosis for even the most expert pathologists. An unacceptably high number of lesions cannot be precisely and reproducibly classified as either entirely benign or malignant by routine histologic and immunohistochemical techniques. The morphologic limitations in the diagnosis of these histologically borderline lesions lead to both under- and over-diagnosis of melanoma. Over-diagnosis of melanoma can lead to inappropriate therapy and psychologic burdens, whereas under-diagnosis can lead to inadequate treatment of a potentially deadly cancer.

The fluorescence in situ hybridization (FISH) molecular assay helps to distinguish these borderline cases by looking for DNA abnormalities present in the vast majority (95%) of melanomas but typically absent in benign nevi. The identification of common chromosomal aberrations in melanomas that are typically absent in benign nevi has led to the use of FISH probes on chromosomes 6 and 11 that can aid in the diagnosis of melanoma in histologically ambiguous cases. The following 4 FISH probes targeting three loci – RREB1 (6p25), MYB (6q23) and CCND1 11q13, and one centomere on two chromosomes accurately distinguished melanoma from benign nevi with a high sensitivity and specificity. The melanoma FISH test can be an important tool in the diagnosis of melanoma in cases with ambiguous or borderline microscopic findings. It has increased sensitivity and specificity compared to other ancillary techniques such as immunohistochemistry. This assay is not to be used as a screening test for obvious melanoma and should always be ordered as a part of a dermatologic pathology consult and interpreted in a working context.

**Methodology**

The test can be performed on routinely processed formalin-fixed paraffin-embedded tissue, and utilizes DNA probe hybridization, fluorescence microscopy and signal enumeration. The test is similar to other diagnostic FISH assays. Short DNA fragments (FISH probes) are hybridized to a 5 µm-thick, formalin-fixed, paraffin-embedded section of a tumor of interest. Overlapping wavelength spectrums of the currently available fluorochromes limit the maximum to four probes that can be concurrently hybridized on a single slide. Nonbound, fluorescently labeled DNA is washed away. The section on a slide is then examined under a fluorescence microscope and demonstrates specific signals enumeration.

**Interpretation**

A distinct fluorescent signal indicates a single copy of the gene or centromere. Ideally, each diploid nucleus will display two signals for each analytical chromosomal locus probed, subject to truncation artifact. Identification of three or more signals for a DNA region of interest is consistent with a gain at that locus. If a DNA region of interest is deleted, less than 2 (1 or 0) signals will be identified. In a typical 4 to 6 µm formalin-fixed, paraffin-embedded (FFPE) section, nuclear truncation occurs. Therefore, for many perfectly normal diploid cells, hybridized probes will be outside the plane of section or overlapping, resulting in less than 2 signals per nucleus. False-positive or false-negative signals can result from imperfect hybridization. Fluorescence microscopy can then be used to ascertain the number of signals per probed locus in each cell nucleus detected by specific fluorescence. Because of the inherent variability of FISH signals, each experiment requires the examination of an adequate number of cells and the implementation of strict quality control measures. The collected data are presented as a percentage of nuclei containing more than 2 copies of a particular locus.
or as a percentage of cells showing an increase or loss of signals in comparison to a probe directed against a centromere region of a chromosome. With appropriate controls, the signal cutoffs (a percentage of cells that must fulfill a particular FISH criterion for a result to be considered abnormal) have been determined and validated for each probe. Rigorously interrogated cutoff values are critical to the robustness of a FISH assay.

At Cleveland Clinic Laboratories, our analyses are performed by an experienced molecular technologist working closely with the molecular technologist to ensure signal enumeration is performed for the appropriate melanocytic target cells. Final interpretation is performed by a board-certified dermatopathologist.

**Limitations of the Assay**

For pathologists and clinicians contemplating incorporating melanoma FISH in their practice, it is critical to understand nuances of the FISH technique, the potential pitfalls, and the ancillary role for this test in the pathologic evaluation of melanocytic lesions. Thus, cutaneous melanoma FISH must not be used as a stand-alone test and must be considered as a diagnostic adjunct to routine pathologic examination of tissue and clinicopathologic correlation.

**References**

4. Gerami P, Zembowicz A. Update on fluorescence in situ hybridization in melanoma; *Arch Pathol Lab Medicine*. 135(7);830-7.

---

**Test Overview**

<table>
<thead>
<tr>
<th>Test Name</th>
<th>FISH for Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering Mnemonic</td>
<td>CMFISH</td>
</tr>
<tr>
<td>Methodology</td>
<td>Short DNA fragments (FISH probes) are hybridized to a 5 µm-thick, formalin-fixed, paraffin-embedded section of a tumor of interest.</td>
</tr>
<tr>
<td>Specimen Requirements</td>
<td>Formalin-fixed paraffin-embedded tissue 5um thick</td>
</tr>
<tr>
<td>Billing Code</td>
<td>89257</td>
</tr>
<tr>
<td>CPT Codes</td>
<td>88368x2</td>
</tr>
</tbody>
</table>

---

**Technical Information Contacts:**

Wendy Nedlik  
216.444.8410  
nedlikw@ccf.org

James Pettay MT (ASCP)  
216.444.9486  
pettayj@ccf.org

**Scientific Information Contacts:**

Steven Billings, MD  
216 444.2826  
billins@ccf.org

Raymond Tubbs, DO  
216.444.2844  
tubbsr@ccf.org